Quicksilver Scientific

Free ground shipping over $50 (excludes HI, AK, & PR)


Unsupported Browser

This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

Milk Thistle References

  1. Abenavoli L, et al. Milk thistle in liver diseases: Past, present, future. Phytother Res. 2010; 24(10): 1423-1432.
  2. Gu X, et al. Molecular mechanisms underlying chemical liver injury. Expert Rev Mol Med. 2012; 14: e4.
  3. Gerber LH, et al. Importance of fatigue and its measurement in chronic liver disease. World J Gastroenterol. 2019; 25(28): 3669-3683.
  4. Acharya C, Bajaj J. Gut microbiota and complications of liver disease. Gastroenterol Clin North Am. 2017; 46(1): 155-169.
  5. Crocenzi FA, et al. Effect of silymarin on biliary bile salt secretion in the rat. Biochem Pharmacol. 2000; 59(8): 1015-1022.
  6. Karimi G, et al. “Silymarin”, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci. 2011; 14(4): 308-317.
  7. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006; 124(5): 491-504.
  8. Dixit N, et al. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharmacol. 2007; 39(4): 172-179.
  9. Vargas-Mendoza N, et al. Hepatoprotective effect of silymarin. World J Hepatol. 2014; 6(3): 144-149.
  10. Surai PF. Silymarin as a natural antioxidant: An overview of the current evidence and perspectives. Antioxidants (Basel). 2015; 4(1): 204-247.
  11. Kim EJ, et al. Silymarin inhibits morphological changes in LPS-stimulated macrophages by blocking the NF-κB pathway. Korean J Physiol Pharmacol. 2015; 19(3): 211-218.
  12. Lovelace ES, et al. Silymarin suppresses cellular inflammation by inducing reparative stress signaling. J Nat Prod. 2015; 78(8): 1990-2000.
  13. Esmaeil N, et al. Silymarin impacts on immune system as an immunomodulator: One key for many locks. Int Immunopharmacol. 2017; 50: 194-201.
  14. Choi YH and Yan GH. Silibinin attenuates mast cell-mediated anaphylaxis-like reactions. Biol Pharm Bull. 2009; 32(5): 868-875.
  15. Liu CH, et al. Antiviral activities of silymarin and derivatives. Molecules. 2019; 24(8): 1552.
  16. de Oliveira DR, et al. In vitro antimicrobial and modulatory activity of the natural products silymarin and silibinin. Biomed Res Int. 2015; 2015: 292797.
  17. Federico A, et al. Silymarin/silybin and chronic liver disease: A marriage of many years. Molecules. 2017; 22(2): 191.
  18. El-Lakkany NM, et al. Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis. Parasit Vectors. 2012; 5: 9.
  19. Perez-Sanchez A, et al. Intestinal permeability study of clinically relevant formulations of Silibinin in Caco-2 Cell monolayers. Int J Mol Sci. 2019; 20(7): 1606.
  20. Kumar N, et al. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune Cells. Pharmacol Rep. 2014; 66(5): 788-798.
  21. Ahn H, et al. Liposomal delivery systems for intestinal lymphatic drug transport. Biomater Res. 2016; 20: 36.
  22. Alyautdin R, et al. Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine. 2014; 9: 795-811.
  23. Spector AA, et al. Membrane lipid composition and cellular function. J Lipid Res. 1985; 26(9): 1015-1035.
Your Cart